ANRO vs IBO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBO Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical while ANRO counters with relative strength in Options & Structure. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, ANRO sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANRO | IBO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $44.4M | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | IBO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +16.7% | Higher Growth | IBO |
| Operating Margin (TTM) Profitability | 0.0% | -12621.0% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 0.0% | 4247.4% | Higher Margin | IBO |
| Return on Equity (ROE) Capital Efficiency | -46.7% | 71.2% | Higher ROE | IBO |
| 52-Week Range Position Momentum | 61% ($11โ$37) | 67% ($0โ$7) | Stronger Trend | IBO |
| Beta / 30D Volatility Risk Regime | 1.95ฮฒ ยท 90% Vol | -6.72ฮฒ ยท 120% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 29.3 / 100 (SELL) | 36.8 / 100 (SELL) | Higher Composite | IBO |